Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Metabolic Syndrome Among Schizophrenic Patients: A Comparative Cross-Sectional Study In The Middle Belt Of Ghana, Angela Owusu-Ansah, Anto Berko Panyin, Christian Obirikorang, Christian Agyare, Emmanuel Acheampong, Simon Kwofie, Enoch Odame Anto, Emmanuella Nsenbah Batu
Metabolic Syndrome Among Schizophrenic Patients: A Comparative Cross-Sectional Study In The Middle Belt Of Ghana, Angela Owusu-Ansah, Anto Berko Panyin, Christian Obirikorang, Christian Agyare, Emmanuel Acheampong, Simon Kwofie, Enoch Odame Anto, Emmanuella Nsenbah Batu
Research outputs 2014 to 2021
The study determined the prevalence ofMetS in patients with schizophrenia at the Psychiatric Unit of the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. This comparative cross-sectional study recruited 348 schizophrenic patients comprising 236 antipsychotic-treated and 112 newly diagnosed treatment-na¨ıve patients. The MetS prevalence was assessed based on World Health Organization (WHO), International Diabetes Federation (IDF), and the National Cholesterol Education Programme, Adult Treatment Panel III (NCEP ATP III) criteria. The overall prevalence of MetS was 14.1%, 20.4%, and 23.6% using NCEP ATP III, WHO, and IDF criteria, respectively, compared to 7.8%, 3.9%, and 2.2% reported in the generalGhanaian population.The prevalence …
A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline In Preclinical Alzheimer’S Disease, Tenielle Porter, Samantha C. Burnham, Greg Savage, Yen Ying Lim, Paul Maruff, Lidija Milicic, Madeline Peretti, David Ames, Colin L. Masters, Ralph N. Martins, Stephanie Rainey-Smith, Christopher C. Rowe, Olivier Salvado, Kevin Taddei, David Groth, Guiseppe Verdile, Victor L. Villemagne, Simon M. Laws
A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline In Preclinical Alzheimer’S Disease, Tenielle Porter, Samantha C. Burnham, Greg Savage, Yen Ying Lim, Paul Maruff, Lidija Milicic, Madeline Peretti, David Ames, Colin L. Masters, Ralph N. Martins, Stephanie Rainey-Smith, Christopher C. Rowe, Olivier Salvado, Kevin Taddei, David Groth, Guiseppe Verdile, Victor L. Villemagne, Simon M. Laws
Research outputs 2014 to 2021
Studies of Alzheimer’s disease risk-weighted polygenic risk scores (PRSs) for cognitive performance have reported inconsistent associations. This inconsistency is particularly evident when PRSs are assessed independent of APOE genotype. As such, the development and assessment of phenotype-specific weightings to derive PRSs for cognitive decline in preclinical AD is warranted. To this end a episodic memory-weighted PRS (emPRS) was derived and assessed against decline in cognitive performance in 226 healthy cognitively normal older adults with high brain Aβ-amyloid burden participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. The effect size for decline in a verbal episodic memory …
Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive And Personalised Medicine, Alyce Russell, Eric Adua, Ivo Ugrina, Simon Laws, Wei Wang
Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive And Personalised Medicine, Alyce Russell, Eric Adua, Ivo Ugrina, Simon Laws, Wei Wang
Research outputs 2014 to 2021
Multiple factors influence immunoglobulin G glycosylation, which in turn affect the glycoproteins’ function on eliciting an anti-inflammatory or pro-inflammatory response. It is prudent to underscore these processes when considering the use of immunoglobulin G N-glycan moieties as an indication of disease presence, progress, or response to therapeutics. It has been demonstrated that the altered expression of genes that encode enzymes involved in the biosynthesis of immunoglobulin G N-glycans, receptors, or complement factors may significantly modify immunoglobulin G effector response, which is important for regulating the immune system. The immunoglobulin G N-glycome is highly heterogenous; however, it is …
Kibra Is Associated With Accelerated Cognitive Decline And Hippocampal Atrophy In Apoe Ε4-Positive Cognitively Normal Adults With High Aβ-Amyloid Burden, Tenielle Porter, Samantha Burnham, Vincent Doré, Greg Savage, Pierrick Bourgeat, Kimberly Begemann, Lidija Milicic, David Ames, Ashley Bush, Paul Maruff, Colin Masters, Christopher Rowe, Stephanie Rainey-Smith, Ralph Martins, David Groth, Guiseppe Verdile, Victor Villemagne, Simon Laws
Kibra Is Associated With Accelerated Cognitive Decline And Hippocampal Atrophy In Apoe Ε4-Positive Cognitively Normal Adults With High Aβ-Amyloid Burden, Tenielle Porter, Samantha Burnham, Vincent Doré, Greg Savage, Pierrick Bourgeat, Kimberly Begemann, Lidija Milicic, David Ames, Ashley Bush, Paul Maruff, Colin Masters, Christopher Rowe, Stephanie Rainey-Smith, Ralph Martins, David Groth, Guiseppe Verdile, Victor Villemagne, Simon Laws
Research outputs 2014 to 2021
A single nucleotide polymorphism, rs17070145, in the KIdney and BRAin expressed protein (KIBRA) gene has been associated with cognition and hippocampal volume in cognitively normal (CN) individuals. However, the impact of rs17070145 on longitudinal cognitive decline and hippocampal atrophy in CN adults at greatest risk of developing Alzheimer’s disease is unknown. We investigated the impact rs17070145 has on the rate of cognitive decline and hippocampal atrophy over six years in 602 CN adults, with known brain Aβ-amyloid levels and whether there is an interactive effect with APOE genotype. We reveal that whilst limited independent effects of KIBRA genotype …